Work

Incidence of Thiopurine-Induced Severe Myelosuppression in a Nationwide Cohort of Patients With Inflammatory Bowel Disease

Year: 2024

Type: article

Abstract: INTRODUCTION: There is paucity of data on the incidence of severe thiopurine (TP)-induced myelosuppression (TIM) among patients with inflammatory bowel disease (IBD). METHODS: Using the Veterans Affairs Healthcare System, we identified patients with IBD with normal pretreatment TP S-methyltransferase levels who received TPs for 6 months and developed severe TIM. RESULTS: Among 73,392 patients with IBD, 14,760 had received TPs, and 2,823 had a normal TP S-methyltransferase level. The incidence rate of severe TIM was 1.25 per 1,000 patient-years. DISCUSSION: The incidence of severe TIM was very low, calling into question the necessity of frequent long-term complete blood count monitoring among patients with IBD on TPs.

Source: The American Journal of Gastroenterology

DOI: 10.14309/ajg.0000000000003141

Authors: Nabeel Khan, Dhruvan Patel, Ramaswamy Sundararajan

Institutions: Philadelphia VA Medical Center, University of Pennsylvania, Mercy Fitzgerald Hospital

Language: English

Topic: Inflammatory Bowel Disease

Subfield: Genetics

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $4,390